Skip to content
MarketScale
‹ Back to IndustriesHealthcare

M&A Healthcare Advisors (MAHA) Exclusively Represents On My Care Home Health in their Sale to Excelin Health

M&A Healthcare Advisors (MAHA), a newly founded boutique merger and acquisition (M&A) advisory group, is proud to announce the sale of On My Care Home Health, a large Home Health agency providing skilled nursing, physical, occupational, and speech therapy, as well as social worker and home aide services. Located in the San Francisco Bay area,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
M&A Healthcare Advisors (MAHA) Exclusively Represents On My Care Home Health in their Sale to Excelin Health

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

M&A Healthcare Advisors (MAHA), a newly founded boutique merger and acquisition (M&A) advisory group, is proud to announce the sale of On My Care Home Health, a large Home Health agency providing skilled nursing, physical, occupational, and speech therapy, as well as social worker and home aide services. Located in the San Francisco Bay area, On My Care was acquired by Excelin Health, a portfolio company of Corinthian Equity Fund II, L.P.

“We are excited to add On My Care to our larger portfolio and continue their tradition of excellence. Andre Ulloa and his team at M&A Healthcare Advisors went above and beyond to shepherd this transaction through closing and were integral to getting the deal done. Andre was the consummate intermediary: attentive, responsive, and consistent throughout the entire process.” – Maureen Spivack, President of MAS Advisory Services, LLC and Board Member of Excelin Health.

While the current M&A market has shown signs of slowing down in recent months, with the right support and guidance, transactions are still occurring. The M&A Healthcare Advisors team was able to create increased value for On My Care, successfully navigate through every phase of the sale process, and identify a buyer with unique synergies who would continue building upon their legacy.

“We regularly speak about how our involvement directly increases the probability of a company being sold and drives the enterprise value of the businesses we represent. The sale process for On My Care Home Health is a direct testament to those principles, our experience, and Andre’s remarkable daily effort to ensure the best outcome for our client”, say Co-Founders Mike Moran & Mark Thomas

This success proves the effectiveness of M&A Healthcare Advisors’ approach only 8 months after their founding.

“The team at M&A Healthcare Advisors [MAHA] was the perfect complement for us as a seller. They matched my work ethic and quick responsiveness. They were supportive, taking on all sale’s process tasks which did not require my involvement, allowing me to focus on my operations.

Although the tangible work product was excellent, what was most impressive to me was their technical consistency and emotional fortitude through a very arduous due diligence process. There were many evenings we would spend on the phone assessing that day’s events and adjusting our approach for the days to come. MAHA introduced me to our transactional attorneys, as well; all the while working side-by-side with the legal team to ensure that every aspect of the purchase agreement was as good as it could be.

In the end, after an eight-month process, all parties walked away with a mutually beneficial deal. I thank that, in large part, to the efforts of MAHA.” – Hans Gill, CEO of On My Care Home Health

About M&A Healthcare Advisors

M&A Healthcare Advisors (MAHA), is a boutique merger and acquisition (M&A) advisory group, focused on the lower-middle market healthcare industry. Our core purpose is to provide comprehensive, efficient, and committed transactional support for emerging or established, lower-middle market healthcare businesses. Our team is highly accessible, experienced, process-driven, and seeks to bring a superior level of guidance to every engagement. We relentlessly advocate for our clients, constantly reinforcing the most essential value: TRUST.

With over 50 successful healthcare transactions in the past five years, the team at M&A Healthcare Advisors has sold companies in a variety of healthcare segments: Behavioral Health, Autism, I/DD, Hospice, Home Health, Home Care, Private Duty, Physical Therapy, Staffing/Medical Recruiting, Not-for-Profits and all types of Pharmacy. Their full suite of services includes Sell-Side Representation, M&A Hourly Consulting, and Expert Valuation services.

Business Contact

Mark Thomas

Partner, Director of Operations

M&A Healthcare Advisors

mthomas@mahealthcareadvisors.com

Media Contact

Matt Santoro

matt@elkordyglobal.com

SOURCE M&A Healthcare Advisors

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512